GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
25.64
-1.30 (-4.81%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally.

It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.

The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development.

It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL, Inc.
GRAIL logo
Country United States
Founded 2016
Industry Diagnostics & Research
Sector Healthcare
Employees 1,000
CEO Robert Ragusa

Contact Details

Address:
1525 O’Brien Drive
Menlo Park, California 94025
United States
Phone 833-694-2553
Website grail.com

Stock Details

Ticker Symbol GRAL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001699031
CUSIP Number 384747101
ISIN Number US3847471014
Employer ID 86-3673636
SIC Code 8071

Key Executives

Name Position
Robert P. Ragusa Chief Executive Officer and Director
Dr. Joshua J. Ofman M.D., M.S.H.S President
Aaron Freidin Chief Financial Officer
Paul Ciccolella Senior Vice President of Research, Development and Operations
Abram Barth J.D., M.P.H. General Counsel
Trish Rowland Vice President of Corporate Communications
Alison Highlander Senior Vice President of Human Resources and Head of People Team
Rodger Currie J.D. Senior Vice President of Government Affairs
Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng President of International Business and BioPharma
Dr. Satnam Alag Ph.D. Senior Vice President of Software Engineering and Chief Security Officer

Latest SEC Filings

Date Type Title
Mar 5, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 5, 2025 10-K Annual Report
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Feb 20, 2025 8-K Current Report
Jan 15, 2025 8-K Current Report
Nov 15, 2024 144 Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 10-Q Quarterly Report